The use of dosimetry in the treatment of differentiated thyroid cancer

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 55, Issue 2, 2011, Pages 107-115

  Lassmann, M ^a   Hanscheid H ^a   Verburg, F A ^a   Luster, M ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

Radiation tolerance; Therapeutics; Thyroid neoplasms

Indexed keywords

IODINE 131;

ABLATION THERAPY; BLOOD DOSIMETRY; BLOOD SAMPLING; BONE MARROW TOXICITY; CANCER RADIOTHERAPY; CANCER THERAPY; DIFFERENTIATED THYROID CANCER; DOSIMETRY; ECHO PLANAR IMAGING; HUMAN; KIDNEY DYSFUNCTION; LESION BASED DOSIMETRY; LEUKOCYTE COUNT; METASTASIS; PATIENT SAFETY; POORLY DIFFERENTIATED THYROID CANCER; RADIATION DOSE DISTRIBUTION; RADIATION SICKNESS; REVIEW; SCINTIGRAPHY; SIALOADENITIS; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THROMBOCYTE COUNT; THYROGLOBULIN BLOOD LEVEL; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME;

CELL DIFFERENTIATION; HUMANS; INDIVIDUALIZED MEDICINE; IODINE RADIOISOTOPES; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; THYROID NEOPLASMS;

EID: 79957633061     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2008;35:1941-59.
2. Meier DA, Brill DR, Becker DV, Clarke SE, Silberstein EB, Royal HD et al. Procedure guideline for therapy of thyroid disease with (131)iodine. J Nucl Med 2002;43:856-61. (Pubitemid 34663310)
3. Tuttle RM, Leboeuf R, Robbins RJ, Qualey R, Pentlow K, Larson SM et al. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med 2006;47:1587-91. (Pubitemid 47545022)
4. Van Nostrand D, Atkins F, Yeganeh F, Acio E, Bursaw R, Wartofsky L. Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. Thyroid 2002;12:121-34.
5. Haq MS, McCready RV, Harmer CL. Treatment of advanced differentiated thyroid carcinoma with high activity radioiodine therapy. Nucl Med Commun 2004;25:799-805. (Pubitemid 39099992)
6. Menzel C, Grunwald F, Schomburg A, Palmedo H, Bender H, Spath G et al. "High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma. J Nucl Med 1996;37:1496-503.
7. Samuel AM, Rajashekharrao B, Shah DH. Pulmonary metastases in children and adolescents with well-differentiated thyroid cancer. J Nucl Med 1998;39:1531-6. (Pubitemid 28459881)
8. Salvatori M, Luster M. Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 2010;37:821-8.
9. Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Chen IW, Sperling MI et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 1983;309:937-41. (Pubitemid 13008961)
10. Maxon HR, 3rd, Smith HS. Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin North Am 1990;19:685-718.
11. Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med 1962;87:171-82.
12. Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF et al. MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 1999;40:37S-61S.
13. Hänscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 2006;47:648-54. (Pubitemid 46768466)
14. Flux GD, Haq M, Chittenden SJ, Buckley S, Hindorf C, Newbold K et al. A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2010;37:270-5.
15. Lassmann M, Hänscheid H, Chiesa C, Hindorf C, Flux G, Luster M. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging 2008;35:1405-12.
16. Leeper RD. Thyroid cancer. Med Clin North Am 1985;69:1079-96.
17. Luster M, Sherman SI, Skarulis MC, Reynolds JR, Lassmann M, Hänscheid H et al. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging 2003;30:1371-7. (Pubitemid 37247954)
18. Hänscheid H, Lassmann M, Luster M, Kloos RT, Reiners C. Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma. Endocr Relat Cancer 2009;16:1283-9.
19. Eschmann SM, Reischl G, Bilger K, Kupferschlager J, Thelen MH, Dohmen BM et al. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. Eur J Nucl Med Mol Imaging 2002;29:760-7.
20. Dorn R, Kopp J, Vogt H, Heidenreich P, Carroll RG, Gulec SA. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. J Nucl Med 2003;44:451-6. (Pubitemid 39586024)
21. 124I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact. Nuklearmedizin 2007;46:121-8.
22. de Keizer B, Brans B, Hoekstra A, Zelissen PM, Koppeschaar HP, Lips CJ et al. Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy. Eur J Nucl Med Mol Imaging 2003;30:367-73. (Pubitemid 36692861)
23. Chiesa C, Castellani MR, Vellani C, Orunesu E, Negri A, Azzeroni R et al. Individualized dosimetry in the management of metastatic differentiated thyroid cancer. Q J Nucl Med Mol Imaging 2009;53:546-61.
24. Luster M, Ladenson P, Pacini F, Schlumberger M, Driedger A, Kloos R et al. Recombinant TSH or thyroid hormone withdrawal? A comparison of I-131 remnant ablation rates in thyroid cancer patients. Eur J Nucl Med Mol Imaging 2004;31:S290-S1.
25. Lee JJ, Chung JK, Kim SE, Kang WJ, Park do J, Lee DS et al. Maximal safe dose of I-131 after failure of standard fixed dose therapy in patients with differentiated thyroid carcinoma. Ann Nucl Med 2008;22:727-34.
26. 131I therapy in patients with advanced differentiated thyroid carcinoma: initial experience. Eur J Nucl Med Mol Imaging 2010;37:896-903.
27. Lassmann M, Hänscheid H, Chiesa C, Luster M, Bombardieri E, Reiners C. Blood dose calculation in radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol I 2007;34:S199-S.
28. De Klerk JM, Oyen WJ. The continuous debate in literature about the usage of iodine-131 dosing for the ablation of thyroid remnants and metastases. Minerva Endocrinol 2009;34:57-69.
29. Verburg FA, Lassmann M, Mäder U, Luster M, Reiners C, Hänscheid H. The absorbed dose to the blood is a better predictor of ablation success than the administered I-131 activity in thyroid cancer patients. Eur J Nucl Med Mol Imaging 2011 [Epub ahead of print].
30. Lassmann M, Hänscheid H, Gassen D, Biko J, Meineke V, Reiners C et al. In vivo formation of gamma-H2AX and 53BP1 DNA repair foci in blood cells after radioiodine therapy of differentiated thyroid cancer. J Nucl Med 2010;51:1318-25.